GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (NAS:DNLI) » Definitions » Market Cap

Denali Therapeutics (Denali Therapeutics) Market Cap

: $2,308.7 Mil (As of Today)
View and export this data going back to 2017. Start your Free Trial

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Denali Therapeutics's share price for the quarter that ended in Dec. 2023 was $21.46. Denali Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 138.4 Mil. Therefore, Denali Therapeutics's market cap for the quarter that ended in Dec. 2023 was $2,969.7 Mil.

Denali Therapeutics's quarterly market cap declined from Jun. 2023 ($4,053.6 Mil) to Sep. 2023 ($2,848.0 Mil) but then increased from Sep. 2023 ($2,848.0 Mil) to Dec. 2023 ($2,969.7 Mil).

Denali Therapeutics's annual market cap declined from Dec. 2021 ($5,453.8 Mil) to Dec. 2022 ($3,781.2 Mil) and declined from Dec. 2022 ($3,781.2 Mil) to Dec. 2023 ($2,969.7 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Denali Therapeutics's Enterprise Value for Today is $1,359.1 Mil.


Denali Therapeutics Market Cap Historical Data

The historical data trend for Denali Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Denali Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,675.63 10,095.68 5,453.82 3,781.21 2,969.74

Denali Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,781.21 3,150.54 4,053.58 2,848.01 2,969.74

Competitive Comparison

For the Biotechnology subindustry, Denali Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Denali Therapeutics Market Cap Distribution

For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Denali Therapeutics's Market Cap falls into.



Denali Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Denali Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$21.46*138.385
=$2,969.7

Denali Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$21.46*138.385
=$2,969.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Denali Therapeutics  (NAS:DNLI) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Denali Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Denali Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Denali Therapeutics (Denali Therapeutics) Business Description

Traded in Other Exchanges
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Executives
Vicki L Sato director 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Carole Ho officer: Chief Medical Officer C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Ryan J. Watts director, officer: President and CEO C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Steve E. Krognes officer: CFO and Treasurer 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Alexander O. Schuth officer: COO and Secretary C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Marc Tessier-lavigne director 1 DNA WAY, SOUTH SAN FRANCISCO CA 94080
Erik Harris director 60 LEVERONI COURT, NOVATO CA 94949
Douglas K Bratton 10 percent owner 201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102
Nancy Thornberry director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Arch Venture Partners Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Viii, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Denali Therapeutics (Denali Therapeutics) Headlines

From GuruFocus

Should Investors Worry About Denali Therapeutics Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 01-06-2023